

News Release

No. 23011

May 25, 2023

Noile-Immune Biotech, Inc.

<https://www.noile-immune.com>

Notice of Approval for Listing on the Tokyo Stock Exchange Growth Market

We are pleased to announce that Noil Immune Biotech, Inc. (Head Office: Minato-ku, Tokyo, CEO: Koji Tamada, Security Code: 4893) has received an approval from Tokyo Stock Exchange, Inc. ("Tokyo Stock Exchange") for the listing of our shares on the Tokyo Stock Exchange Growth Market. The date of listing on the Tokyo Stock Exchange Growth Market is scheduled for Wednesday, June 28, 2023.

On this occasion, we would like to express our gratitude to all the stakeholders for their continuous support and trust in us.

We have been on a mission to "Create the Future to Overcome Cancer," and engaged in R&D of novel cancer immunotherapies such as CAR-T and TCR-T for solid cancer, employing our PRIME (Proliferation-Inducing and Migration-Enhancing) technology. As a public-listed company, we will proactively advance efforts to deliver truly effective treatments to patients suffering from cancer worldwide as soon as possible.

For further details, please refer to the "New Listing" page on the website of Japan Exchange Group.

<https://www.jpx.co.jp/listing/stocks/new/index.html>

Note: This document is a press release to publicly announce the approval of our stock to be listed on the Tokyo Stock Exchange Growth Market, and has not been prepared for the purpose of soliciting investment or other conduct of similar nature whether in Japan or overseas. When making investment decisions for the issuance and offering of our shares as resolved at our Board of Directors meeting on May 25, 2023, investors are urged to make such decisions at their own discretion after reviewing the "Prospectus for the Issuance of New Shares and the Secondary Offering of Shares" (and revisions thereto) prepared by us. "Prospectus for the Issuance of New Shares and the Secondary Offering of Shares" (and revisions thereto) may be obtained from the underwriters.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities referred to in this press release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of an English language prospectus prepared in accordance with the Securities Act that may be obtained from the seller, and that will contain detailed information about us and our management, as well as our financial statements. However, we will not register the securities in the press release under the Securities Act.